Prophylactic human papillomavirus (HPV) vaccination has been recommended for routine use in US females since 2006 and males since 2011 for the prevention of anogenital HPV infections.1 Although studies have demonstrated high vaccine efficacy in reducing prevalence of oral HPV infection,2 prevention of oral HPV infections and oropharyngeal cancers is not a vaccine indication because of lack of randomized trials. Also lacking are surveillance studies for herd protection against oral HPV infections.3
Chaturvedi AK, Graubard BI, Broutian T, et al. Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016. JAMA. 2019;322(10):977–979. doi:10.1001/jama.2019.10508
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: